Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger immune response than a conventional mRNA vaccine for up to one year and at a ...

David Carbone, Director of the James Thoracic Oncology Center and Professor of Internal Medicine at The Ohio State University ...

The FDA has extended its approval of UCB’s BIMZELX to three new indications, extending the use of the drug to a total of four ...

London-based biopharmaceutical company Vicebio has announced a $100 million series B financing led by TCGX and with the participation of Goldman Sachs Alternatives, Avoro Ventures, venBio, UniQuest ...